

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/217082 A1

(43) International Publication Date
13 October 2022 (13.10.2022)

(51) International Patent Classification:

A61K 39/395 (2022.01) A61P 35/00 (2022.01)
A61K 39/00 (2022.01) C07K 16/28 (2022.01)
A61K 9/00 (2022.01)

(21) International Application Number:

PCT/US2022/024063

(22) International Filing Date:

08 April 2022 (08.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/173,224 09 April 2021 (09.04.2021) US

(71) Applicant (for all designated States except US): **AMPHIVENA THERAPEUTICS, INC.** [US/US]; c/o Ravix Group, 226 Airport Pkwy Suite 400, San Jose, California 95110 (US).

(72) Inventor: **SMITH, Victoria**; 19 Dwight Rd, Burlingame, California 94010 (US).

(74) Agent: **HALSTEAD, David P.** et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: DOSING OF BISPECIFIC T CELL ENGAGER

(57) Abstract: Methods for reducing myeloid-derived suppressor cells and activating T cells in a patient and for treating a patient suffering from a solid tumor are described. The methods entail administering a CD3/CD33 T cell engager.



WO 2022/217082 A1